趋化因子 (C-X-C) 基序配体 9 (CXCL9) 是淋巴细胞运输相关的趋化因子之一。尽管CXCL9在招募肿瘤周围效应T细胞（分化簇4（CD4）和CD8 T细胞）和自然杀伤细胞（NK细胞）方面具有免疫治疗潜力，但CXCL9的实际应用由于其免疫毒性和缺乏体内稳定性。为了克服这些限制，我们设计并合成了Pt-Te纳米棒（PtTeNRs），它在体内环境的生理条件下表现出优异的光热转换效率和稳定的CXCL9有效负载特性。我们利用已开发的 PtTeNR 的独特理化特性开发了基于 CXCL9 的免疫治疗策略。研究表明，负载PtTeNR的CXCL9在肿瘤中有效积累，随后以持续的方式释放，并成功招募效应T细胞对指定肿瘤组织进行免疫治疗。此外，还观察到光热 (PT) 疗法和抗程序性细胞死亡蛋白 1 (aPD-1) 抗体之间存在协同效应。在这项研究中，我们证明了基于 PtTeNR 的 CXCL9、PT 和 aPD-1 抗体三联疗法在癌症的所有阶段（包括 1-4 期和肿瘤复发）均具有出色的肿瘤抑制效果。

The chemokine (C-X-C) motif ligand 9 (CXCL9) is one of the lymphocyte-traffic-involved chemokines. Despite the immunotherapeutic potential of CXCL9 for recruiting effector T cells (cluster of differentiation 4+ (CD4+) and CD8+ T cells) and natural killer cells (NK cells) around the tumors, practical applications of CXCL9 have been limited because of its immune toxicity and lack of stability in vivo. To overcome these limitations, we designed and synthesized Pt-Te nanorods (PtTeNRs), which exhibited excellent photothermal conversion efficiency with stable CXCL9 payload characteristics under the physiological conditions of in vivo environments. We developed a CXCL9-based immunotherapy strategy by utilizing the unique physicochemical properties of developed PtTeNRs. The investigation revealed that the PtTeNR-loaded CXCL9 was effectively accumulated in the tumor, subsequently released in a sustained manner, and successfully recruited effector T cells for immunotherapy of the designated tumor tissue. In addition, a synergistic effect was observed between the photothermal (PT) therapy and antiprogrammed cell death protein 1 (aPD-1) antibody. In this study, we demonstrated that PtTeNR-based CXCL9, PT, and aPD-1 antibody trimodal therapy delivers an outstanding tumor suppression effect in all stages of cancer, including phases 1-4 and tumor recurrence.